
Opinion|Videos|March 24, 2025
Addressing the Most Common Concerns Patients and Caregivers Have in Late-Line RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how patients and caregivers at the late-line treatment stage commonly struggle with profound concerns about diminishing treatment options, increased uncertainty about prognosis, managing complex and often cumulative side effects, financial toxicity from years of therapy, caregiver burnout, practical challenges of more frequent hospitalizations, anxiety about becoming refractory to novel agents, navigating clinical trial eligibility, maintaining hope while being realistic and balancing aggressive treatment approaches with quality of life considerations as therapeutic choices narrow.
Advertisement
Video content above is prompted by the following:
- What common concerns do patients and caregivers have at this late-line stage of treatment?
Advertisement
Related to this article

The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.

A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.

Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.

The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.

The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Advertisement
Advertisement
Trending on CURE
1
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
2
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
3
What Is a Personalized Cancer Vaccine? What Patients Should Know
4
New Tumor Type May Help Identify High-Risk Small Cell Lung Cancer
5

